ImmVirX
New Lambton
About ImmVirX
ImmVirX hopes to advance a new generation of cancer treatments,By developing a novel oncolytic immunotherapy that targets cancer indications with high unmet need
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $50.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2023)
- Website: immvirx.com
- Phone: [email protected]
Industries & Categories
Health Care, Health Diagnostics
Canonical: https://fsome.com/organization/immvirx-30801 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.